144 related articles for article (PubMed ID: 11955650)
1. The predictive value of neuroendocrine markers and p53 for response to chemotherapy and survival in patients with advanced non-small cell lung cancer.
Gajra A; Tatum AH; Newman N; Gamble GP; Lichtenstein S; Rooney MT; Graziano SL
Lung Cancer; 2002 May; 36(2):159-65. PubMed ID: 11955650
[TBL] [Abstract][Full Text] [Related]
2. Use of neuroendocrine markers, p53, and HER2 to predict response to chemotherapy in patients with stage III non-small cell lung cancer: a Cancer and Leukemia Group B study.
Graziano SL; Tatum A; Herndon JE; Box J; Memoli V; Green MR; Kern JA
Lung Cancer; 2001; 33(2-3):115-23. PubMed ID: 11551406
[TBL] [Abstract][Full Text] [Related]
3. [The value of neuroendocrine markers for response to therapy and survival in patients with advanced non-small cell lung cancer].
Petrović M; Ilić N; Baskić D
Srp Arh Celok Lek; 2010; 138(1-2):37-42. PubMed ID: 20422910
[TBL] [Abstract][Full Text] [Related]
4. Neuroendocrine differentiation as a prognostic factor in non-small cell lung cancer.
Carles J; Rosell R; Ariza A; Pellicer I; Sanchez JJ; Fernandez-Vasalo G; Abad A; Barnadas A
Lung Cancer; 1993 Dec; 10(3-4):209-19. PubMed ID: 7521264
[TBL] [Abstract][Full Text] [Related]
5. Predictive value of expression of P53, Bcl-2 and lung resistance-related protein for response to chemotherapy in non-small cell lung cancers.
Harada T; Ogura S; Yamazaki K; Kinoshita I; Itoh T; Isobe H; Yamashiro K; Dosaka-Akita H; Nishimura M
Cancer Sci; 2003 Apr; 94(4):394-9. PubMed ID: 12824911
[TBL] [Abstract][Full Text] [Related]
6. The use of neuroendocrine immunoperoxidase markers to predict chemotherapy response in patients with non-small-cell lung cancer.
Graziano SL; Mazid R; Newman N; Tatum A; Oler A; Mortimer JA; Gullo JJ; DiFino SM; Scalzo AJ
J Clin Oncol; 1989 Oct; 7(10):1398-406. PubMed ID: 2550590
[TBL] [Abstract][Full Text] [Related]
7. [Neuroendocrine differentiation as a survival prognostic factor in advanced non-small cell lung cancer].
Petrović M; Tomić I; Ilić S
Vojnosanit Pregl; 2007 Aug; 64(8):525-9. PubMed ID: 17874719
[TBL] [Abstract][Full Text] [Related]
8. Prognostic implications of neuroendocrine differentiation and hormone production in patients with Stage I nonsmall cell lung carcinoma.
Pelosi G; Pasini F; Sonzogni A; Maffini F; Maisonneuve P; Iannucci A; Terzi A; De Manzoni G; Bresaola E; Viale G
Cancer; 2003 May; 97(10):2487-97. PubMed ID: 12733148
[TBL] [Abstract][Full Text] [Related]
9. ERCC1 expression does not predict survival and treatment response in advanced stage non-small cell lung cancer cases treated with platinum based chemotherapy.
Ozdemir O; Ozdemir P; Veral A; Uluer H; Ozhan MH
Asian Pac J Cancer Prev; 2013; 14(8):4679-83. PubMed ID: 24083725
[TBL] [Abstract][Full Text] [Related]
10. FHIT and p53 status and response to platinum-based treatment in advanced non-small cell lung cancer.
Cortinovis DL; Andriani F; Livio A; Fabbri A; Perrone F; Marcomini B; Pilotti S; Mariani L; Bidoli P; Bajetta E; Roz L; Sozzi G
Curr Cancer Drug Targets; 2008 Aug; 8(5):342-8. PubMed ID: 18690840
[TBL] [Abstract][Full Text] [Related]
11. [Influence of chemiotherapeutic protocol and neuroendocrine differentiation on metastatic non-small cell lung cancer treatment results].
Tomić I; Petrović M; Plavec G; Ilić S
Vojnosanit Pregl; 2007 Sep; 64(9):591-6. PubMed ID: 17969813
[TBL] [Abstract][Full Text] [Related]
12. [Correlation analysis among expression of ERCC-1, metallothionein, p53 and platinum resistance and prognosis in advanced non-small cell lung cancer].
Huang PY; Liang XM; Lin SX; Luo RZ; Hou JH; Zhang L
Ai Zheng; 2004 Jul; 23(7):845-50. PubMed ID: 15248926
[TBL] [Abstract][Full Text] [Related]
13. The prognostic significance of circulating neuroendocrine markers chromogranin a, pro-gastrin-releasing peptide and neuron-specific enolase in patients with advanced non-small-cell lung cancer.
Nisman B; Heching N; Biran H; Barak V; Peretz T
Tumour Biol; 2006; 27(1):8-16. PubMed ID: 16340245
[TBL] [Abstract][Full Text] [Related]
14. Heat shock protein 70 as a predictive marker for platinum-based adjuvant chemotherapy in patients with resected non-small cell lung cancer.
Park TS; Kim HR; Koh JS; Jang SH; Hwang YI; Yoon HI; Chung JH; Kim CH; Kim SS; Kim WS; Jo J; Lee JC; Choi CM
Lung Cancer; 2014 Nov; 86(2):262-7. PubMed ID: 25261232
[TBL] [Abstract][Full Text] [Related]
15. Vascular endothelial growth factor, p53, Rb, Bcl-2 expression and response to chemotherapy in advanced non-small cell lung cancer.
Ludovini V; Gregorc V; Pistola L; Mihaylova Z; Floriani I; Darwish S; Stracci F; Tofanetti FR; Ferraldeschi M; Di Carlo L; Ragusa M; Daddi G; Tonato M
Lung Cancer; 2004 Oct; 46(1):77-85. PubMed ID: 15364135
[TBL] [Abstract][Full Text] [Related]
16. Neuroendocrine differentiation is an independent prognostic factor in chemotherapy-treated nonsmall cell lung carcinoma.
Schleusener JT; Tazelaar HD; Jung SH; Cha SS; Cera PJ; Myers JL; Creagan ET; Goldberg RM; Marschke RF
Cancer; 1996 Apr; 77(7):1284-91. PubMed ID: 8608504
[TBL] [Abstract][Full Text] [Related]
17. Reactive Oxygen Species Modulator 1 (Romo1) Predicts Poor Outcomes in Advanced Non-small Cell Lung Cancer Patients Treated with Platinum-Based Chemotherapy.
Lee SH; Choi SI; Lee JS; Kim CH; Jung WJ; Lee EJ; Min KH; Hur GY; Lee SH; Lee SY; Kim JH; Lee SY; Shin C; Shim JJ; Kang KH; In KH
Cancer Res Treat; 2017 Jan; 49(1):141-149. PubMed ID: 27188201
[TBL] [Abstract][Full Text] [Related]
18. Results after surgery in undifferentiated large cell carcinoma of the lung: the role of neuroendocrine expression.
Wertzel H; Grahmann PR; Bansbach S; Lange W; Hasse J; Böhm N
Eur J Cardiothorac Surg; 1997 Nov; 12(5):698-702. PubMed ID: 9458138
[TBL] [Abstract][Full Text] [Related]
19. Excision-repair-cross-complement-1 protein as a prognostic factor in patients with advanced non-small cell lung cancer treated with platinum-based first-line chemotherapy.
Vassalou H; Stathopoulos E; Fiolitaki G; Koutsopoulos A; Voutsina A; Georgoulias V; Mavroudis D
Lung Cancer; 2013 Nov; 82(2):324-9. PubMed ID: 23993732
[TBL] [Abstract][Full Text] [Related]
20. Serpin b3 is associated with poor survival after chemotherapy and is a potential novel predictive biomarker in advanced non-small-cell lung cancer.
Urquhart G; Kerr KM; Nicolson M; Loo PS; Sharma R; Shrimali R; Petty RD
J Thorac Oncol; 2013 Dec; 8(12):1502-9. PubMed ID: 24389432
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
